The hair relaxer MDL is one of the largest active mass tort cases in the country, with over 11,000 plaintiffs and bellwether trials taking shape in 2026. Key developments include a federal judge personally selecting 10 test cases, a new medical monitoring class action, and expert battles that will heavily influence settlement outcomes.
- Over 11,000 cases are now consolidated in federal court
- A judge has selected 10 representative “bellwether” cases to go to trial first
- A new class action seeks medical monitoring for people not yet diagnosed with cancer
- Expert testimony fights (called Daubert hearings) are the next major milestone
The hair relaxer lawsuit MDL is one of the most closely watched mass tort cases in the country right now.
With more than 11,000 plaintiffs, a federal judge personally stepping in to shape the trial process, and expert battles just getting underway, 2026 is shaping up to be a pivotal year for this litigation.
Key Takeaways about the 2026 Hair Relaxer Cancer Lawsuit Update
This update breaks down the most recent developments, what they mean for plaintiffs already in the MDL, and what women who used these products may still want to know about their options.
- The hair relaxer MDL has grown to more than 11,371 plaintiffs, making it the third-largest MDL in the United States.
- Judge Rowland took direct control of the bellwether selection process in April 2026, personally choosing 10 representative cases.
- The core legal question in these trials is whether repeated use of chemical hair relaxers caused reproductive cancers, particularly uterine cancer.
- A new class action filed in March 2026 seeks medical monitoring for former users who have not yet been diagnosed with cancer.
- The litigation is entering the expert discovery phase, which typically shapes how and whether large mass tort cases settle.
The Hair Relaxer MDL in 2026: A Major Case Reaching a Turning Point
The hair relaxer cancer lawsuit has grown into one of the most significant mass tort cases in recent memory.
As of April 2026, more than 11,371 plaintiffs are part of the federal multidistrict litigation (MDL), a legal structure that consolidates similar lawsuits from across the country into one court. That puts this case among the three largest MDLs in the United States.
MDL stands for multidistrict litigation. It is a process that allows cases with similar legal claims to be grouped together for pretrial proceedings, which saves time and resources for both the courts and the people filing claims.
Each plaintiff still has their own individual case, but evidence gathering and key legal questions are resolved together.
The central claim in this litigation is serious: that repeated use of chemical hair relaxers, products that have been marketed for decades primarily to Black women, caused reproductive cancers, including uterine cancer and ovarian cancer.
The manufacturers of these products, plaintiffs allege, knew or should have known about these risks and failed to warn consumers.
For the tens of thousands of women affected, this litigation represents a chance at accountability.
What Is a Bellwether Trial and Why Does It Matter?
One of the most important recent developments is the selection of 10 bellwether cases. If you have not encountered this term before, here is what it means: a bellwether trial is a test case selected to go to a jury first, ahead of the thousands of other similar lawsuits.
These test trials serve a specific purpose. They give both sides a realistic picture of how juries respond to the core claims. Did the product cause cancer? How much should a plaintiff be compensated? Those answers, even from a small number of trials, tend to drive larger settlement conversations.
Judge Rowland took an unusually direct approach here. Rather than allowing the parties to take turns selecting cases throughout April as originally planned, she personally chose all 10 cases at once. Her reasoning was straightforward: the bellwether pool needs to be genuinely representative of the broader litigation.
To keep the trials focused, the court excluded several categories of cases from the pool:
- Cases involving only one or two defendants
- Cases where a plaintiff has memory loss, mental health issues, or learning disabilities
- Cases where the plaintiff has a second, separate cancer diagnosis
- Cases where the plaintiff is also pursuing a talc (talcum powder) claim
The goal behind these exclusions is to give juries a clean look at the core question: did hair relaxers cause cancer, and what are those injuries worth? Complicated medical histories or overlapping litigation could distract from that central issue.
This careful case selection signals that Judge Rowland wants bellwether verdicts that can actually move the needle toward resolution for all plaintiffs, not just those 10.
A Second Front: The Medical Monitoring Class Action
Not everyone harmed by hair relaxers has a cancer diagnosis yet. That reality is at the heart of a significant new development filed in March 2026.
A group of 11 plaintiffs representing seven separate proposed class actions asked the court to certify a medical monitoring class.
If successful, this would allow the case to proceed on behalf of a much broader group: former hair relaxer users who used the products but have not been diagnosed with cancer.
What is medical monitoring?
It is a legal claim that says: even if you are not sick today, a company that exposed you to something harmful should pay for ongoing medical testing to catch a disease early, rather than making you wait until you receive a diagnosis.
For women who used chemical hair relaxers regularly, especially over many years, the argument is that they face a statistically elevated risk of developing reproductive cancers.
Court-supervised medical monitoring, plaintiffs argue, would ensure those women get regular screenings without paying out of pocket.
This class action would run on a separate track from the individual cancer lawsuits. If certified, it could create a second layer of resolution in this litigation, one that addresses a population of women who may currently have no legal recourse simply because they have not yet fallen ill.
Expert Testimony: The Battle That Will Shape Settlements
The litigation is now entering what attorneys call the expert phase, one of the most consequential stages in any mass tort case.
At a March 2026 status hearing, Judge Rowland focused heavily on preparing for what are called Daubert hearings. Daubert refers to the legal standard courts use to determine whether scientific expert testimony is sufficiently reliable to be presented to a jury. In plain terms, both sides will try to knock out each other’s experts.
Why does this matter so much? Because in cancer litigation, expert testimony is often everything.
Plaintiffs need qualified scientists to testify that the product caused the disease. Defendants need their own experts to argue that the science does not support that conclusion. If a judge rules that a key plaintiff expert cannot testify, it can dramatically weaken the case and change the settlement calculus.
The court set clear rules for these expert challenges:
- Defendants can file up to 100 pages challenging the plaintiffs’ ten experts
- Plaintiffs can respond with either one 100-page brief or ten 10-page responses
- Defendants then get 50 pages for a reply
Judge Rowland also pushed the parties to agree on basic facts not in dispute, such as how the products were marketed, what warnings were given, and how they were labeled.
The idea is to avoid wasting trial time on things both sides already know to be true. That kind of efficiency signals a judge who is serious about moving this case toward resolution.
The Corporate Deposition Fight
Another dispute brewing in the litigation is about how companies will be questioned under oath about their marketing decisions.
Plaintiffs want to conduct corporate depositions, a process where a company must designate a representative to answer questions on behalf of the entire organization. These depositions can be revealing.
They force company representatives to explain what the corporation knew about product risks, when they knew it, and how they chose to communicate with consumers.
Defendants have proposed replacing some of these depositions with written stipulations, which are agreed statements of limited facts. Plaintiffs pushed back. Written stipulations, they argue, tend to eliminate the kind of candid, under-oath testimony that reveals the full story of how a product was developed, sold, and kept on the market.
If the parties cannot agree, the plaintiffs have indicated they will proceed with depositions. This fight over how corporate knowledge gets presented to a jury could significantly affect how these trials unfold.
What This Means for Women Who Used Hair Relaxers
If you or a loved one used chemical hair relaxers regularly and have been diagnosed with uterine cancer, ovarian cancer, or another reproductive cancer, these developments are directly relevant to you.
The litigation is no longer in its early stages. With over 11,000 plaintiffs, bellwether trials in the works, and expert battles underway, the case is moving toward a resolution phase. That does not mean there is urgency to rush, but it does mean that understanding your rights and options sooner rather than later matters.
A Chicago hair relaxer cancer lawyer can help you assess whether your diagnosis, your history of product use, and the timing of your potential claim all align with what is being litigated in this MDL.
There is also the medical monitoring class action to watch. If you used hair relaxers regularly and have not been diagnosed with cancer, you may eventually have legal options for accessing medical screening. That is still in early stages, but it is worth following.
FAQs about Hair Relaxer Lawsuit Update 2026
Here are answers to some of the questions we hear most often about the status of this litigation.
What cancers are linked to hair relaxer use?
The primary cancers at the center of this litigation are uterine cancer and ovarian cancer. Some claims also involve other reproductive cancers.
The core scientific argument is that chemicals in hair relaxers, including certain endocrine-disrupting compounds, may interfere with hormonal systems in ways that increase cancer risk with repeated, long-term exposure.
What is an MDL and how is it different from a class action?
An MDL (multidistrict litigation) is not the same as a class action. In a class action, one lawsuit is filed on behalf of many people who share the same legal claims and receive the same outcome. In an MDL, each plaintiff still has their own individual lawsuit with their own facts and damages.
The cases are just grouped together for efficiency during pretrial proceedings like discovery and expert challenges.
What happens after the bellwether trials?
Bellwether verdicts provide both sides with real data on how juries evaluate these cases. If juries consistently find in favor of plaintiffs and award significant damages, defendants have a stronger incentive to settle remaining cases.
If verdicts are mixed or damages are low, the litigation may continue for years. The results of these 10 test cases will be closely watched by everyone involved.
Can I still file a hair relaxer lawsuit in 2026?
Statutes of limitations vary by state, and the deadline to file depends on factors like when you were diagnosed and where you live. If you believe you may have a claim, speaking with an attorney as soon as possible is the best way to understand whether you still have time to file.
How long will the hair relaxer lawsuit take to resolve?
There is no definitive timeline. Large MDLs like this one often take several years to fully resolve, especially when they involve complex scientific questions like cancer causation. The bellwether trial process, expected to begin in 2026 or 2027, will give the best indication of whether and when a broader resolution might occur.
Talk to Our Team About Your Hair Relaxer Cancer Claim
If you or someone you love has been diagnosed with uterine cancer or another reproductive cancer after years of using chemical hair relaxers, you deserve to understand your legal options. This litigation is real, it is growing, and it is moving forward.
At our firm, we have spent more than two decades fighting for people whose lives were changed by a cancer diagnosis tied to a product they trusted. We know this territory. We know what it takes to hold corporations accountable. And we know how to be a steady, honest presence for our clients at one of the hardest moments of their lives.
You do not need to figure this out alone. Reach out to us today at (312) 466-1669 for a free, confidential consultation. We will listen, be honest with you about what we see, and help you decide what makes sense for you and your family.
